Natera Inc (NTRA)vsVuzix Corp Cmn Stk (VUZI)
NTRA
Natera Inc
$194.24
-11.64%
HEALTHCARE · Cap: $30.71B
VUZI
Vuzix Corp Cmn Stk
$3.11
+8.74%
TECHNOLOGY · Cap: $239.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 36618% more annual revenue ($2.31B vs $6.28M). VUZI leads profitability with a 0.0% profit margin vs -9.0%. NTRA earns a higher WallStSmart Score of 31/100 (F).
NTRA
Avoid31
out of 100
Grade: F
VUZI
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NTRA.
Margin of Safety
+43.1%
Fair Value
$4.34
Current Price
$3.11
$1.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.8% year-over-year
Revenue surging 76.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 15.8x book value
0.0% earnings growth
ROE of -14.3% — below average capital efficiency
Currently unprofitable
Trading at 10.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.
Bull Case : VUZI
The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.
Bear Case : VUZI
The primary concerns for VUZI are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
NTRA carries more volatility with a beta of 1.57 — expect wider price swings.
VUZI is growing revenue faster at 76.3% — sustainability is the question.
NTRA generates stronger free cash flow (38M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NTRA scores higher overall (31/100 vs 26/100) and 39.8% revenue growth. VUZI offers better value entry with a 43.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Vuzix Corp Cmn Stk
TECHNOLOGY · CONSUMER ELECTRONICS · USA
Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?